🔎 Trials Near Me

Home › Crohn's Disease › Indiana

Pag-aaral pangklinika para sa Crohn's Disease sa Indiana

13 pag-aaral para sa Crohn's Disease ang naghahanap ng mga kalahok sa mga site sa Indiana.

Mga Lungsod sa Indiana

Opisyal na teksto ng pag-aaral (English)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • Indiana University Health University Hospital ( Site 5022), Indianapolis
Nagre-recruitPhase 3
Edad 16 hanggang 80 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastroenterology Health Partners /ID# 284145, New Albany
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07697456

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Indiana University Health University Hospital /ID# 278129, Indianapolis
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06548542

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • IU Health University Hospital, Indianapolis
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07196722

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • Riley Hospital for Children, Indianapolis
Nagre-recruitPhase 3
Edad 3 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06663332

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Indiana University Health University Hospital, Indianapolis
  • Gastroenterology Health Partners, New Albany
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
Nagre-recruitPhase 3
Edad 16 hanggang 80 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
Nagre-recruitPhase 3
Edad 16 hanggang 80 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  • Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
Nagre-recruitPhase 3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT05995353

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Riley Childrens Hospital, Indianapolis
Nagre-recruitPhase 3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05509777

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis
Nagre-recruitPhase 3
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT06332534

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Riley Hospital for Children at Indiana University Health, Indianapolis
Nagre-recruitPhase 4
Edad 6 hanggang 17 · Lahat ng kasarian · Na-update May 27, 2026 · NCT05781152

Precise Infliximab Exposure and Pharmacodynamic Control

  • Riley Hospital for Children, Indianapolis
Nagre-recruitPhase 2/3
Edad 6 hanggang 22 · Lahat ng kasarian · Na-update May 5, 2026 · NCT05660746

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.